Ex vivo comparison of V.A.C.® Granufoam Silver™ and V.A.C.® Granufoam™ loaded with a first-in-class bis-dialkylnorspermidine-terphenyl antibiofilm agent

Kaden B. Rawson; Travis Neuberger; Tyler B. Smith; Isaac J. Bell; Ryan E. Looper; Paul R. Sebahar; Travis J. Haussener; Hariprasada Reddy Kanna Reddy; Brad M. Isaacson; John Shero; Paul F. Pasquina; Dustin L. Williams

Biofilm (Dec 2023)

Ex vivo comparison of V.A.C.® Granufoam Silver™ and V.A.C.® Granufoam™ loaded with a first-in-class bis-dialkylnorspermidine-terphenyl antibiofilm agent

Kaden B. Rawson,
Travis Neuberger,
Tyler B. Smith,
Isaac J. Bell,
Ryan E. Looper,
Paul R. Sebahar,
Travis J. Haussener,
Hariprasada Reddy Kanna Reddy,
Brad M. Isaacson,
John Shero,
Paul F. Pasquina,
Dustin L. Williams

Affiliations

Kaden B. Rawson: Department of Orthopaedics, University of Utah, Salt Lake City, UT, USA; Bone and Biofilm Research Lab, University of Utah, Salt Lake City, UT, USA; Carle Illinois College of Medicine, University of Illinois, Urbana, IL, USA
Travis Neuberger: Department of Orthopaedics, University of Utah, Salt Lake City, UT, USA; Bone and Biofilm Research Lab, University of Utah, Salt Lake City, UT, USA; Department of Biomedical Engineering, University of Utah, UT, USA; Carle Illinois College of Medicine, University of Illinois, Urbana, IL, USA
Tyler B. Smith: Department of Orthopaedics, University of Utah, Salt Lake City, UT, USA; Bone and Biofilm Research Lab, University of Utah, Salt Lake City, UT, USA
Isaac J. Bell: Department of Orthopaedics, University of Utah, Salt Lake City, UT, USA; Bone and Biofilm Research Lab, University of Utah, Salt Lake City, UT, USA
Ryan E. Looper: Department of Chemistry, University of Utah, Salt Lake City, UT, USA; Curza Global, LLC, Salt Lake City, UT, USA
Paul R. Sebahar: Department of Chemistry, University of Utah, Salt Lake City, UT, USA; Curza Global, LLC, Salt Lake City, UT, USA
Travis J. Haussener: Department of Chemistry, University of Utah, Salt Lake City, UT, USA; Curza Global, LLC, Salt Lake City, UT, USA
Hariprasada Reddy Kanna Reddy: Department of Chemistry, University of Utah, Salt Lake City, UT, USA; Curza Global, LLC, Salt Lake City, UT, USA
Brad M. Isaacson: Bone and Biofilm Research Lab, University of Utah, Salt Lake City, UT, USA; The Center for Rehabilitation Sciences Research, Department of Physical Medicine and Rehabilitation, Uniformed Services University, Bethesda, MD, USA; The Geneva Foundation, Tacoma, WA, USA
John Shero: Extremity Trauma and Amputation Center of Excellence, Joint Base San Antonio Fort Sam Houston, San Antonio, TX, USA
Paul F. Pasquina: The Center for Rehabilitation Sciences Research, Department of Physical Medicine and Rehabilitation, Uniformed Services University, Bethesda, MD, USA; Department of Rehabilitation, Walter Reed National Military Medical Center, Bethesda, MD, USA
Dustin L. Williams: Department of Orthopaedics, University of Utah, Salt Lake City, UT, USA; Bone and Biofilm Research Lab, University of Utah, Salt Lake City, UT, USA; Department of Biomedical Engineering, University of Utah, UT, USA; Curza Global, LLC, Salt Lake City, UT, USA; The Center for Rehabilitation Sciences Research, Department of Physical Medicine and Rehabilitation, Uniformed Services University, Bethesda, MD, USA; Department of Pathology, University of Utah, Salt Lake City, UT, USA; Corresponding author. Department of Orthopaedics, Biomedical Polymers Research Building, 20 S 2030 E Rm 205, Salt Lake City, UT, 84112, USA.

Journal volume & issue: Vol. 6
p. 100142

Abstract

Read online

Implementation of negative pressure wound therapy (NPWT) as a standard of care has proven efficacious in reducing both the healing time and likelihood of nosocomial infection among pressure ulcers and traumatic, combat-related injuries. However, current formulations may not target or dramatically reduce bacterial biofilm burden following therapy. The purpose of this study was to determine the antibiofilm efficacy of an open-cell polyurethane (PU) foam (V.A.C.® Granufoam™) loaded with a first-in-class compound (CZ-01179) as the active release agent integrated via lyophilized hydrogel scaffolding. An ex vivo porcine excision wound model was designed to perform antibiofilm efficacy testing in the presence of NPWT. PU foam samples loaded with a 10.0% w/w formulation of CZ-01179 and 0.5% hyaluronic acid were prepared and tested against current standards of care: V.A.C.® Granufoam Silver™ and V.A.C.® Granufoam™. We observed statistically significant reduction of methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii biofilms with the CZ-01179 antibiofilm foam in comparison to current standard of care foams. These findings motivate further development of an antibiofilm PU foam loaded with CZ-01179.

Published in Biofilm

ISSN: 2590-2075 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Technology: Chemical technology: Biotechnology; Science: Microbiology
Website: https://www.journals.elsevier.com/biofilm

About the journal

Abstract

Keywords